Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

61. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke.

Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. ACP Journal Club. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My (...) Bibliography Citation manager Format Create File 1 selected item: 23247951 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Dec 18;157(12):JC6-2. doi: 10.7326/0003-4819-157-12-201212180-02002. ACP Journal Club. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. 1 , . 1 University

Annals of Internal Medicine2012

62. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Biancari F (...) , Airaksinen KE, Lip GY CRD summary The authors concluded that, contrary to analyses of randomised controlled trial data, observational studies showed that clopidogrel before coronary artery bypass grafting increased the risks of death after surgery, reoperation for bleeding, blood loss and needing a blood transfusion. The limitations of the evidence available, and the differences between studies, make the reliability of the authors' conclusions unclear. Authors' objectives To assess the impact

DARE.2012

63. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study

Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study 22942294 2012 11 15 2013 01 15 2016 11 25 1468-201X 98 23 2012 Dec Heart (British Cardiac Society) Heart Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary (...) arteRY bypaSS occlusion After off-pump procedures) randomised study. 1710-5 10.1136/heartjnl-2012-302449 To determine the individual variability in the response to aspirin and/or clopidogrel and its impact on graft patency after off-pump coronary artery bypass grafting. A single-centre prospective randomised controlled study designed according to the Consolidated Standards of Reporting Trials statement. Randomisation was obtained by a computer-generated algorithm. University medical school in Italy. 300 patients who

EvidenceUpdates2012

64. Outcomes of patients receiving clopidogrel prior to cardiac surgery

Outcomes of patients receiving clopidogrel prior to cardiac surgery Outcomes of patients receiving clopidogrel prior to cardiac surgery Outcomes of patients receiving clopidogrel prior to cardiac surgery Vorobcsuk A, Aradi D, Farkasfalvi K, Horvath IG, Komocsi A CRD summary This review found that concomitant treatment of clopidogrel prior to surgery in patients who underwent cardiac surgery was associated with higher mortality and significantly increased risk of bleeding-related complications (...) . Uncertainty about the completeness of the search and flaws in the presentation of the results mean that the results and conclusions should be interpreted with some caution. Authors' objectives To assess the effect of treatment with clopidogrel on clinical outcomes in patients having cardiac surgery. Searching PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 2001 to May 2010. Search terms were reported. There were no language restrictions. Reference lists

DARE.2012

65. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis

Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, Qin YY, He J CRD summary The addition of aspirin to clopidogrel resulted in small relative reductions (...) in major cardiovascular events, myocardial infarction and stroke, but it resulted in a relative increase in major bleeding events. The authors' conclusion reflects the evidence presented and seems reliable. Authors' objectives To evaluate the benefits and harms of combined aspirin and clopidogrel therapy on major cardiovascular outcomes. Searching PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched until March, 2011; search terms were reported. To locate

DARE.2012

66. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines

Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions While combination therapy with clopidogrel and ASA remains the basis

Health Technology Assessment (HTA) Database.2012

67. Tranexamic Acid in On-Pump Coronary Artery Bypass Grafting Without Clopidogrel and Aspirin Cessation: Randomized Trial and 1-Year Follow-Up

Tranexamic Acid in On-Pump Coronary Artery Bypass Grafting Without Clopidogrel and Aspirin Cessation: Randomized Trial and 1-Year Follow-Up 22959576 2013 02 26 2013 04 23 2013 11 21 1552-6259 95 3 2013 Mar The Annals of thoracic surgery Ann. Thorac. Surg. Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up. 795-802 10.1016/j.athoracsur.2012.07.015 S0003-4975(12)01627-X Dual antiplatelet therapy is widely (...) used in patients with coronary artery disease and increases the risk of excessive bleeding and transfusion in those undergoing coronary artery bypass grafting (CABG). The study was a prospective, randomized, double-blinded and placebo-controlled trial. Patients undergoing primary and isolated on-pump CABG with their last dose of clopidogrel and aspirin less than 7 days preoperatively were randomly assigned to receive tranexamic acid (15 mg/kg before surgical incision and 15 mg/kg after protamine

EvidenceUpdates2012

68. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack 22572911 2012 06 12 2012 08 23 2014 11 20 1524-4539 125 23 2012 Jun 12 Circulation Circulation Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. 2914-21 10.1161/CIRCULATIONAHA.111.082727 Patients with acute coronary syndromes and history of stroke or transient ischemic attack (TIA) have an (...) increased rate of recurrent cardiac events and intracranial hemorrhages. We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial. Of the 18 624 randomized patients, 1152 (6.2%) had a history of stroke or TIA. Such patients had higher rates of myocardial infarction (11.5% versus 6.0%), death (10.5% versus 4.9%), stroke (3.4% versus 1.2

EvidenceUpdates2012

69. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial 22261200 2012 02 28 2012 04 19 2014 11 20 1524-4539 125 8 2012 Feb 28 Circulation Circulation Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. 978-86 10.1161/CIRCULATIONAHA.111.032912 The clinical significance (...) of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial. The primary end point rates were higher for individuals on a PPI (n=6539) compared with those

EvidenceUpdates2012

70. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Kwok CS, Nijjar RS, Loke YK CRD summary The authors concluded (...) that proton-pump inhibitors were associated with a reduction in adverse gastrointestinal events (particularly haemorrhages) in patients who were receiving dual antiplatelet therapy (clopidogrel and aspirin). Potential bias in the review process and reliance on lower quality study designs mean that the reliability of this conclusion is uncertain. Authors' objectives To evaluate the effects of proton-pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel. Searching PubMed, EMBASE

DARE.2012

71. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial 22090660 2011 12 02 2012 01 31 2014 11 20 1522-9645 32 23 2011 Dec European heart journal Eur. Heart J. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. 2933-44 10.1093/eurheartj/ehr422 AIMS More intense platelet-directed therapy for acute coronary (...) ) receptor antagonist, or clopidogrel in addition to aspirin. Patients randomized to ticagrelor and clopidogrel had similar rates of PLATO major bleeding (11.6 vs. 11.2%; P = 0.43), TIMI major bleeding (7.9 vs. 7.7%, P = 0.56) and GUSTO severe bleeding (2.9 vs. 3.1%, P = 0.22). Procedure-related bleeding rates were also similar. Non-CABG major bleeding (4.5 vs. 3.8%, P = 0.02) and non-procedure-related major bleeding (3.1 vs. 2.3%, P = 0.05) were more common in ticagrelor-treated patients, primarily

EvidenceUpdates2012

72. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ CRD summary The review noted that there was a discrepancy between the results of randomised controlled trials and observational studies when comparing clopidogrel plus proton pump inhibitor (...) with clopidogrel alone on cardiovascular and stroke outcomes; more research was required to adequately assess effects. Given substantial differences between the included studies and limitations in the evidence base, the authors' conclusions are appropriate. Authors' objectives To compare the effects of the combination of proton pump inhibitors and clopidogrel versus clopidogrel alone for antiplatelet treatment. Searching MEDLINE, EMBASE, The Cochrane Library, clinical trials registers, cardiology websites

DARE.2012

73. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions

Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions Steiner S, Moertl D, Chen L, Coyle D, Wells GA CRD summary (...) This review found potentially relevant differences in efficacy and bleeding risk between antiplatelet drugs prasugrel, ticagrelor and high-dose clopidogrel in patients undergoing percutaneous coronary interventions, but that these conclusions were not definitive as they were not based on direct comparisons of treatments. Despite some limitations, the authors' conclusions reflect the evidence and are likely to be reliable. Authors' objectives To compare the efficacy and safety of prasugrel, ticagrelor

DARE.2012

74. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 22920930 2012 10 04 2012 10 16 2015 11 19 1533-4406 367 14 2012 Oct 04 The New England journal of medicine N. Engl. J. Med. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 1297-309 10.1056/NEJMoa1205512 The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has (...) not been delineated. In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction

NEJM2012

75. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.

Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. 22931315 2012 08 30 2012 09 07 2016 12 15 1533-4406 367 9 2012 Aug 30 The New England journal of medicine N. Engl. J. Med. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. 817-25 10.1056/NEJMoa1204133 Lacunar infarcts are a frequent type of stroke caused mainly by cerebral small-vessel disease. The effectiveness of antiplatelet therapy for secondary prevention has not been defined. We (...) conducted a double-blind, multicenter trial involving 3020 patients with recent symptomatic lacunar infarcts identified by magnetic resonance imaging. Patients were randomly assigned to receive 75 mg of clopidogrel or placebo daily; patients in both groups received 325 mg of aspirin daily. The primary outcome was any recurrent stroke, including ischemic stroke and intracranial hemorrhage. The participants had a mean age of 63 years, and 63% were men. After a mean follow-up of 3.4 years, the risk

NEJM2012 Full Text: Link to full Text with Trip Pro

76. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. 23117779 2012 11 02 2012 11 08 2016 10 17 1538-3598 308 17 2012 Nov 07 JAMA JAMA Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. 1785-94 10.1001/jama.2012.17312 The relationship of platelet function testing (...) measurements with outcomes in patients with acute coronary syndromes (ACS) initially managed medically without revascularization is unknown. To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel. Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel. Of 9326 participants

JAMA2012

77. Safety and effectiveness of prasugrel compared to clopidogrel for patients with acute coronary syndrome: A Systematic Review

Safety and effectiveness of prasugrel compared to clopidogrel for patients with acute coronary syndrome: A Systematic Review Home - Monash Health Find a Location Latest news We are delighted to begin construction on the Victorian Heart Hospital, Australia’s first dedicated state-of-the art cardiac facility. Your health Protect your health and safety while you travel this holiday season by planning ahead and preparing for the unexpected. Our children’s hospital Monash Children’s Hospital is one

Monash Health Evidence Reviews2012

78. Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness

Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Project page URL Indexing Status Subject indexing assigned by CRD MeSH Acute Coronary Syndrome; Adenosine; Adults; Platelet Aggregation Inhibitors

Health Technology Assessment (HTA) Database.2011

79. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar

Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar 21958886 2011 09 30 2012 01 05 2013 11 21 1558-3597 58 15 2011 Oct 04 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary (...) percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. 1592-9 10.1016/j.jacc.2011.06.044 The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarction (STEMI). Given the high thrombotic risk of patients with STEMI, greater platelet inhibition may improve

EvidenceUpdates2011

80. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Siller-Matula JM, Huber K, Christ G, Schror (...) K, Kubica J, Herkner H, Jilma B CRD summary This review concluded that high clopidogrel doses (600mg) reduced the rate of major adverse cardiovascular events without increasing the incidence of major bleeding events in patients undergoing percutaneous coronary intervention one month after the start of therapy. Although these conclusions accurately reflect the results of the review, their reliability may be limited by concerns about publication bias and review methodology. Authors' objectives

DARE.2011